Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Average Recommendation of “Moderate Buy” by Brokerages

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and nine have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $41.7778.

Several equities research analysts have issued reports on TEVA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. Piper Sandler restated an “overweight” rating and issued a $42.00 price target (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, April 30th. Bank of America increased their price target on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 9th. Barclays increased their price target on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Finally, UBS Group increased their price target on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 30th.

Teva Pharmaceutical Industries Trading Down 1.1%

NYSE TEVA opened at $33.24 on Monday. The stock has a 50-day simple moving average of $33.73 and a 200 day simple moving average of $32.39. The company has a market capitalization of $38.22 billion, a PE ratio of 24.99, a P/E/G ratio of 4.11 and a beta of 0.84. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. Teva Pharmaceutical Industries has a 12 month low of $14.99 and a 12 month high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. The business had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. Research analysts forecast that Teva Pharmaceutical Industries will post 1.97 EPS for the current year.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, EVP Richard Daniell sold 30,000 shares of the stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total value of $1,062,000.00. Following the completion of the sale, the executive vice president directly owned 55,755 shares in the company, valued at $1,973,727. This represents a 34.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Eliyahu Sharon Kalif sold 106,563 shares of the company’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $34.10, for a total value of $3,633,798.30. Following the transaction, the executive vice president directly owned 65,621 shares of the company’s stock, valued at $2,237,676.10. This represents a 61.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 465,931 shares of company stock valued at $16,332,989. 0.54% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Aster Capital Management DIFC Ltd acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $25,000. Cornerstone Planning Group LLC boosted its position in shares of Teva Pharmaceutical Industries by 547.1% during the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock worth $27,000 after buying an additional 755 shares during the period. Allworth Financial LP boosted its position in shares of Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after buying an additional 329 shares during the period. Grove Bank & Trust boosted its position in shares of Teva Pharmaceutical Industries by 300.0% during the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after buying an additional 750 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Teva Pharmaceutical Industries by 51.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after buying an additional 345 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.